Pioglitazone improves left ventricular diastolic function in subjects with diabetes

Geoffrey D Clarke, Carolina Solis-Herrera, Marjorie Molina-Wilkins, Sandra Martinez, Aurora Merovci, Eugenio Cersosimo, Robert J Chilton, Patricia Iozzo, Amalia Gastaldelli, Muhammad A Abdul-ghani, Ralph A Defronzo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

OBJECTIVE To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twelve subjectswith T2Dand 12with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-D-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment.Myocardial function and transmitral early diastolic relation/atrial contraction (E/A) flow ratio were measured with magnetic resonance imaging. RESULTS Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 762 and 762mmHg, respectively (P < 0.05); and increased whole-body insulinstimulated glucose uptake by 71% (3.4 ± 1.3 to 5.8 ± 2.1 mg/kg · min; P < 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75% (0.24 ± 0.14 to 0.42 ± 0.13 μmol/min · g; P < 0.01) and myocardial perfusion by 16% (0.95 ± 0.16 to 1.10 ± 0.25 mL/min · g; P < 0.05). Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P < 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 ± 6 to 66 ± 7%) and stroke volume increased significantly (71 ± 20 to 80 ± 20 L/min; both P < 0.05). CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.

Original languageEnglish (US)
Pages (from-to)1530-1536
Number of pages7
JournalDiabetes Care
Volume40
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

pioglitazone
Left Ventricular Function
Type 2 Diabetes Mellitus
Insulin Resistance
Glucose
Perfusion
Blood Pressure
Glucose Clamp Technique
Deoxyglucose
Cardiac Output
Positron-Emission Tomography
Stroke Volume
Research Design
Magnetic Resonance Imaging
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., ... Defronzo, R. A. (2017). Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care, 40(11), 1530-1536. https://doi.org/10.2337/dc17-0078

Pioglitazone improves left ventricular diastolic function in subjects with diabetes. / Clarke, Geoffrey D; Solis-Herrera, Carolina; Molina-Wilkins, Marjorie; Martinez, Sandra; Merovci, Aurora; Cersosimo, Eugenio; Chilton, Robert J; Iozzo, Patricia; Gastaldelli, Amalia; Abdul-ghani, Muhammad A; Defronzo, Ralph A.

In: Diabetes Care, Vol. 40, No. 11, 01.11.2017, p. 1530-1536.

Research output: Contribution to journalArticle

Clarke, GD, Solis-Herrera, C, Molina-Wilkins, M, Martinez, S, Merovci, A, Cersosimo, E, Chilton, RJ, Iozzo, P, Gastaldelli, A, Abdul-ghani, MA & Defronzo, RA 2017, 'Pioglitazone improves left ventricular diastolic function in subjects with diabetes', Diabetes Care, vol. 40, no. 11, pp. 1530-1536. https://doi.org/10.2337/dc17-0078
Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017 Nov 1;40(11):1530-1536. https://doi.org/10.2337/dc17-0078
Clarke, Geoffrey D ; Solis-Herrera, Carolina ; Molina-Wilkins, Marjorie ; Martinez, Sandra ; Merovci, Aurora ; Cersosimo, Eugenio ; Chilton, Robert J ; Iozzo, Patricia ; Gastaldelli, Amalia ; Abdul-ghani, Muhammad A ; Defronzo, Ralph A. / Pioglitazone improves left ventricular diastolic function in subjects with diabetes. In: Diabetes Care. 2017 ; Vol. 40, No. 11. pp. 1530-1536.
@article{e28688874d2d46cbbf3cd48a8918a423,
title = "Pioglitazone improves left ventricular diastolic function in subjects with diabetes",
abstract = "OBJECTIVE To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twelve subjectswith T2Dand 12with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-D-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment.Myocardial function and transmitral early diastolic relation/atrial contraction (E/A) flow ratio were measured with magnetic resonance imaging. RESULTS Pioglitazone reduced HbA1c by 0.9{\%}; decreased systolic and diastolic blood pressure by 762 and 762mmHg, respectively (P < 0.05); and increased whole-body insulinstimulated glucose uptake by 71{\%} (3.4 ± 1.3 to 5.8 ± 2.1 mg/kg · min; P < 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75{\%} (0.24 ± 0.14 to 0.42 ± 0.13 μmol/min · g; P < 0.01) and myocardial perfusion by 16{\%} (0.95 ± 0.16 to 1.10 ± 0.25 mL/min · g; P < 0.05). Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P < 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 ± 6 to 66 ± 7{\%}) and stroke volume increased significantly (71 ± 20 to 80 ± 20 L/min; both P < 0.05). CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.",
author = "Clarke, {Geoffrey D} and Carolina Solis-Herrera and Marjorie Molina-Wilkins and Sandra Martinez and Aurora Merovci and Eugenio Cersosimo and Chilton, {Robert J} and Patricia Iozzo and Amalia Gastaldelli and Abdul-ghani, {Muhammad A} and Defronzo, {Ralph A}",
year = "2017",
month = "11",
day = "1",
doi = "10.2337/dc17-0078",
language = "English (US)",
volume = "40",
pages = "1530--1536",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Pioglitazone improves left ventricular diastolic function in subjects with diabetes

AU - Clarke, Geoffrey D

AU - Solis-Herrera, Carolina

AU - Molina-Wilkins, Marjorie

AU - Martinez, Sandra

AU - Merovci, Aurora

AU - Cersosimo, Eugenio

AU - Chilton, Robert J

AU - Iozzo, Patricia

AU - Gastaldelli, Amalia

AU - Abdul-ghani, Muhammad A

AU - Defronzo, Ralph A

PY - 2017/11/1

Y1 - 2017/11/1

N2 - OBJECTIVE To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twelve subjectswith T2Dand 12with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-D-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment.Myocardial function and transmitral early diastolic relation/atrial contraction (E/A) flow ratio were measured with magnetic resonance imaging. RESULTS Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 762 and 762mmHg, respectively (P < 0.05); and increased whole-body insulinstimulated glucose uptake by 71% (3.4 ± 1.3 to 5.8 ± 2.1 mg/kg · min; P < 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75% (0.24 ± 0.14 to 0.42 ± 0.13 μmol/min · g; P < 0.01) and myocardial perfusion by 16% (0.95 ± 0.16 to 1.10 ± 0.25 mL/min · g; P < 0.05). Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P < 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 ± 6 to 66 ± 7%) and stroke volume increased significantly (71 ± 20 to 80 ± 20 L/min; both P < 0.05). CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.

AB - OBJECTIVE To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twelve subjectswith T2Dand 12with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-D-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment.Myocardial function and transmitral early diastolic relation/atrial contraction (E/A) flow ratio were measured with magnetic resonance imaging. RESULTS Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 762 and 762mmHg, respectively (P < 0.05); and increased whole-body insulinstimulated glucose uptake by 71% (3.4 ± 1.3 to 5.8 ± 2.1 mg/kg · min; P < 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75% (0.24 ± 0.14 to 0.42 ± 0.13 μmol/min · g; P < 0.01) and myocardial perfusion by 16% (0.95 ± 0.16 to 1.10 ± 0.25 mL/min · g; P < 0.05). Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P < 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 ± 6 to 66 ± 7%) and stroke volume increased significantly (71 ± 20 to 80 ± 20 L/min; both P < 0.05). CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.

UR - http://www.scopus.com/inward/record.url?scp=85031490199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031490199&partnerID=8YFLogxK

U2 - 10.2337/dc17-0078

DO - 10.2337/dc17-0078

M3 - Article

C2 - 28847910

AN - SCOPUS:85031490199

VL - 40

SP - 1530

EP - 1536

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -